| Bioactivity | Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain[1]. |
| Target | Cav 3.2 |
| Invitro | Cav 3.2 inhibitor 1 (compound 3a, 0.3 μM) inhibits Cav3.2 activities by about 50% in Cav3.2-transfected HEK293 cells[1].Cav 3.2 inhibitor 1 (1 and 10 μM) displays little binding affinity to D2 receptors[1].Cav 3.2 inhibitor 1 (0.01-1 μM) inhibits T-currents in Cav3.1-expressing HEK293 cells[1]. |
| In Vivo | Cav 3.2 inhibitor 1 (compound 3a, 10 mg/kg, i.p.) suppresses Cav3.2-dependent somatic and visceral pain in mice[1].Cav 3.2 inhibitor 1 (8 nmol/mouse, i.c.v.) has no effect on long-lasting catalepsy in mice[1]. Animal Model: |
| Name | Cav 3.2 inhibitor 1 |
| Formula | C32H39N3O |
| Molar Mass | 481.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yoshihito Kasanami, et al. Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D 2 receptors for treatment of somatic and visceral pain. Eur J Med Chem. 2022 Aug 27;243:114716. |